Next-Generation Immunotherapeutic Approaches for Diffuse Midline Gliomas

Diffuse midline gliomas (DMGs) are among the most aggressive and devastating brain tumors affecting children. Current treatments offer only limited benefit, and survival rates have barely improved over the past decades. These tumors arise in a critical, hard to reach region of the brain and actively suppress the immune system, preventing it from recognizing and fighting the cancer. This project aims to develop new immune based treatments designed specifically for DMG. Our goal is to help the child’s own defenses more effectively recognize and attack tumor cells and to prevent the tumor from actively shutting those defenses down. We have identified a key resistance mechanism that allows DMG to escape even the most advanced immunotherapies, and we are engineering our treatments to overcome it directly. Importantly, this mechanism is shared across all current treatment approaches, making it a uniquely rational and high impact target.

The research team will explore two complementary approaches: specially engineered oncolytic viruses that selectively infect tumor cells and trigger a strong immune response from within the tumor itself, and immune cells genetically trained to recognize DMG cells and remain active even in the highly suppressive tumor environment. Both strategies are built on clinical platforms already tested in children with DMG, providing a direct and credible path toward future trials. Because these therapies are delivered directly into the brain and intended for children, safety is a central priority. The team will carefully evaluate how treatments affect normal brain cells, neural circuits, and function, ensuring that new therapies not only extend survival but also preserve cognition, learning, and quality of life. This project does not start from scratch. It builds on a decade of translational research, first in human clinical experience, and a clear scientific rationale to advance treatments that are both more effective and safer. The goal is to give children with DMG a real and meaningful chance.